SCHEMBL6200633

SCHEMBL6200633

CCCCC(C=O)(CCCC)CS(=O)(=O)c1ccccc1Cc1ccc(OC)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.38
MMP12 P39900 7/20 0.38
MMP8 P22894 6/20 0.38
MMP13 P45452 6/20 0.38
MMP14 P50281 6/20 0.38
MMP16 P51512 6/20 0.38
MMP9 P14780 6/20 0.38
MMP1 P03956 4/20 0.38
MMP3 P08254 4/20 0.38
ADAM17 P78536 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
NSD2 O96028 1/20 0.37
LTA4H P09960 1/20 0.37
CNR2 P34972 1/20 0.35
MAOB P27338 1/20 0.34
CNR1 P21554 1/20 0.34
HTT P42858 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6201198 0.84 AR (0.36) MMP13MMP9MMP1L3MBTL1CNR2
SCHEMBL6202055 0.83 CNR1 (0.38) LTA4HCNR2CNR1ALDH1A1
SCHEMBL6201097 0.83 CNR1 (0.38) LTA4HCNR2CNR1ALDH1A1
SCHEMBL6202677 0.83 TBXA2R (0.40) KMT2AMEN1L3MBTL1CNR2CNR1
SCHEMBL8893617 0.76 CNR1 (0.34) MMP13MMP9MMP1L3MBTL1CNR2
SCHEMBL8202222 0.76 CNR1 (0.38) MMP2MMP13MMP1MMP3ADAM17
SCHEMBL6203147 0.73 RET (0.33) KMT2AMEN1L3MBTL1MAPT
SCHEMBL6202226 0.72 ALDH1A1 (0.41) KMT2AMEN1L3MBTL1HTTALDH1A1
SCHEMBL6201836 0.72 ALDH1A1 (0.44) KMT2AMEN1L3MBTL1CNR2HTT
SCHEMBL3659180 0.70 LTA4H (0.51) MMP2MMP12MMP8MMP13MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1425279-A4 METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES SEARLE LLC (US) 2005-10-26 EP disclosed
US-20050090543-A1 Method for the preparation of tetrahydrobenzothiepines PHARMACIA CORPORATION (US) 2005-04-28 US disclosed
US-6794544-B2 APICAL SODIUM CO- DEPENDENT BILE ACID TRANSPORTER (ASBT) INHIBITORS PHARMACIA CORPORATION 2004-09-21 US disclosed
US-20040110761-A1 Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders G.D. SEARLE LLC 2004-06-10 US disclosed
EP-1425279-A2 METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES G.D. Searle LLC (US) 2004-06-09 EP disclosed
US-20040082647-A1 Method for the preparation of tetrahydrobenzothiepines G.D. SEARLE, LLC 2004-04-29 US disclosed
US-20030236406-A1 Method for the preparation of tetrahydrobenzothiepines BABIAK KEVIN A (US) 2003-12-25 US disclosed
US-20030232834-A1 Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders KELLER BRADLEY T (US) 2003-12-18 US disclosed
WO-2003022804-A9 METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES SEARLE LLC (US) 2003-12-18 WO disclosed
US-20030199515-A1 Method for the preparation of crystalline tetrahydrobenzothiepines G.D. SEARLE, LLC (US) 2003-10-23 US disclosed
US-6586434-B2 Method for the preparation of tetrahydrobenzothiepines G.D. SEARLE, LLC 2003-07-01 US disclosed
WO-2003022804-A2 METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES G.D. SEARLE LLC (US) 2003-03-20 WO disclosed
EP-1286984-A2 METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES Pharmacia Corporation (US) 2003-03-05 EP disclosed
US-20020061888-A1 Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders G.D. SEARLE LLC 2002-05-23 US disclosed
US-20020032329-A1 Method for the preparation of tetrahydrobenzothiepines G.D. SEARLE LLC 2002-03-14 US disclosed
WO-2001068637-A2 METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES PHARMACIA CORPORATION (US) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110761-A1 Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders SLC10A1, HMGCR, SLC10A2 MMP2 1902/4885MMP12 1436/4885MMP8 2704/4885
US-20030199515-A1 Method for the preparation of crystalline tetrahydrobenzothiepines TPMT, MPST, SULT1A1 MMP2 3175/4885MMP12 4550/4885MMP8 3976/4885
US-20030232834-A1 Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders TOP2A, TOP2B, TYMP MMP2 357/4885MMP12 610/4885MMP8 845/4885
US-20020032329-A1 Method for the preparation of tetrahydrobenzothiepines TMT1A, THOP1, BBOX1 MMP2 2492/4885MMP12 3570/4885MMP8 3290/4885
US-20020061888-A1 Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders SLC10A1, HMGCR, SLC10A2 MMP2 2275/4885MMP12 1296/4885MMP8 2730/4885
US-20050090543-A1 Method for the preparation of tetrahydrobenzothiepines TMT1A, THOP1, BBOX1 MMP2 2492/4885MMP12 3570/4885MMP8 3290/4885
US-20030236406-A1 Method for the preparation of tetrahydrobenzothiepines TMT1A, THOP1, BBOX1 MMP2 2456/4885MMP12 3553/4885MMP8 3261/4885
US-20040082647-A1 Method for the preparation of tetrahydrobenzothiepines TMT1A, THOP1, BBOX1 MMP2 2492/4885MMP12 3570/4885MMP8 3290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.